市场调查报告书
商品编码
1411272
局部麻醉市场规模- 按药物类型(利多卡因、布比卡因、罗哌卡因、丙胺卡因、阿替卡因)、给药途径(局部、注射)、应用(牙科、急诊医学、皮肤科)、最终用途和全球预测,2024-2032年Local Anesthesia Market Size - By Drug Type (Lidocaine, Bupivacaine, Ropivacaine, Prilocaine, Articaine), Route of Administration (Topical, Injectable), Application (Dental, Emergency Medicine, Dermatology), End-use & Global Forecast, 2024-2032 |
由于各医学专业的外科手术数量不断增加,加上需要疼痛管理的老龄化人口不断扩大,预计 2024 年至 2032 年局部麻醉市场规模将以 4.2% 的CAGR扩大。更高的技术进步,例如长效和微创麻醉技术的发展,正在提高患者的舒适度和满意度。
此外,慢性疼痛和牙科手术的日益普及将加速产品的采用。最近,医疗保健专业人员越来越意识到局部麻醉在最大限度地减少全身副作用和加速患者復健方面的好处。药物配方和递送方法方面正在进行的研究和创新也将继续有利于该行业的成长。例如,2021 年 12 月,Hikma Pharmaceuticals PLC 推出了盐酸布比卡因注射液,旨在用于手术、牙科和口腔手术、诊断和治疗手术以及产科手术。
局部麻醉产业依药物类型、给药途径、应用、最终用途和地区进行分类。
就药物类型而言,阿替卡因药物领域的行业份额预计从 2024 年到 2032 年将以 4.3% 的CAGR增长。这种增长可归因于阿替卡因的快速起效和延长的持续时间,以提高牙科和医疗程序的功效。此外,由于阿替卡因在疼痛管理和改善患者治疗效果的有效性,人们越来越偏好阿替卡因,这将有助于增加产品需求。
预计从 2024 年到 2032 年,妇产科应用领域的局部麻醉市场份额将达到创纪录的 4%CAGR。这是由于在各种妇科手术和产科干预期间越来越多地使用局部麻醉来进行疼痛管理。此外,越来越重视改善患者舒适度和尽量减少全身副作用将促进该细分市场的成长。
从地区来看,预计 2024 年至 2032 年欧洲局部麻醉市场的CAGR为 4.3%。这一增长可归因于外科手术的增加、人口老龄化以及对局部麻醉益处的认识提高。医疗保健基础设施的不断进步,加上对以患者为中心的护理的高度重视,也将推动区域市场的成长。
Local anesthesia market size is projected to expand at 4.2% CAGR from 2024 to 2032, due to the rising number of surgical procedures across various medical specialties, coupled with the expanding aging population requiring pain management. The higher technological advancements, such as the development of long-acting and less invasive anesthesia techniques is leading to enhanced patient comfort and satisfaction.
Additionally, the increasing prevalence of chronic pain conditions and dental procedures will accelerate the product adoption. Lately, there has been growing awareness among healthcare professionals about the benefits of local anesthesia in minimizing systemic side effects and accelerating patient recovery. The ongoing research and innovation in drug formulations and delivery methods will also continue to benefit the industry growth. For instance, in December 2021, Hikma Pharmaceuticals PLC launched Bupivacaine HCl Injection, intended for use in surgeries, dental and oral procedures, diagnostic and therapeutic procedures, as well as obstetrical procedures.
The local anesthesia industry is categorized into drug type, route of administration, application, end-use, and region.
With respect to drug type, the industry share from the articaine drug segment is estimated to rise at 4.3% CAGR from 2024 to 2032. The growth can be ascribed to the rapid onset and prolonged duration of articaine for enhancing efficacy in dental and medical procedures. Moreover, the increasing preference for articaine due to its effectiveness in pain management and improved patient outcomes will contribute to the product demand.
Local anesthesia market share from the obstetrics and gynecology application segment is projected record 4% CAGR from 2024 to 2032. This is due to the increasing use of local anesthesia for pain management during various gynecological procedures and obstetric interventions. In addition, the rising emphasis on improving patient comfort and minimizing systemic side effects will boost the segment growth.
Regionally, the Europe local anesthesia market is projected to depict 4.3% CAGR from 2024 to 2032. The growth can be attributed to the rise in surgical procedures, aging population, and increased awareness of the benefits of local anesthesia. The rising advancements in healthcare infrastructure coupled with the strong focus on patient-centric care will also drive the regional market growth.